Diagnosis and Treatment of Postpartum Haemorrhage

A Race Against Time: Clinical Reference Card

Source: The Lancet | Specialty: General Internal Medicine

🎯 EXECUTIVE SUMMARY

Postpartum haemorrhage (PPH) is defined as a blood loss of 500 mL or more within 24 hours after birth, or 1000 mL or more following a caesarean section, with severe PPH typically exceeding 1000 mL, irrespective of delivery mode. It remains a leading cause of maternal morbidity and mortality worldwide, making its rapid diagnosis and immediate, systematic management critically important. The “race against time” metaphor highlights the exponential increase in adverse outcomes with delayed intervention. Effective management relies on a multidisciplinary approach, accurate assessment of blood loss, and prompt initiation of a protocolized treatment pathway, addressing the underlying causes quickly. (The Lancet, 2024)

🔬 STUDY OVERVIEW

This article series from The Lancet emphasizes the global burden of PPH and the imperative for standardized, evidence-based practices to reduce its impact. It consolidates contemporary understanding of PPH pathophysiology, risk factors, diagnostic strategies, and the comprehensive spectrum of therapeutic interventions. A key theme is the importance of preparedness, including having trained personnel, essential medications, and equipment readily available. The series advocates for a proactive, rather than reactive, approach to PPH management, integrating best practices from high-resource settings and adapting them for low-resource environments to achieve equitable maternal health outcomes. (The Lancet, 2024)

📊 KEY RESULTS

Identified Causes (The 4 T’s)

Tone (Atony): Uterine atony is the most common cause (approx. 70-80%), where the uterus fails to contract adequately after birth, leading to continued bleeding from the placental site. (The Lancet, 2024)
Trauma: Lacerations of the cervix, vagina, or perineum, or uterine rupture. (The Lancet, 2024)
Tissue: Retained placental tissue or clots preventing effective uterine contraction. (The Lancet, 2024)
Thrombin: Coagulopathy, either pre-existing or acquired during labour (e.g., severe pre-eclampsia, HELLP syndrome, massive transfusion). (The Lancet, 2024)

Impact of Delayed Diagnosis & Treatment

Delay in diagnosis and treatment leads to increased blood loss, greater risk of hypovolemic shock, organ dysfunction, need for massive transfusion, coagulopathy, hysterectomy, and maternal death. Early recognition and initiation of a standardized PPH protocol are crucial to mitigating these risks. (The Lancet, 2024)

Multidisciplinary Team Approach

Emphasizes the critical role of obstetricians, anaesthesiologists, nurses, midwives, and blood bank personnel working cohesively under a clear PPH management algorithm. (The Lancet, 2024)

🩺 DIAGNOSTIC CRITERIA

Definition

Primary PPH: Blood loss ≥ 500 mL within 24 hours of vaginal birth or ≥ 1000 mL after caesarean section. (The Lancet, 2024)
Severe PPH: Blood loss ≥ 1000 mL, irrespective of delivery mode. (The Lancet, 2024)
Secondary PPH: Abnormal or excessive bleeding from 24 hours postpartum up to 12 weeks postpartum. (The Lancet, 2024)

Clinical Assessment

Quantitative Blood Loss (QBL): Crucial for accurate diagnosis, using calibrated collection bags, weighing pads, and measuring blood in drapes. Visual estimation is often inaccurate and underestimates actual loss. (The Lancet, 2024)
Vital Signs: Tachycardia, hypotension, and tachypnea are late signs of hypovolemic shock. Regular monitoring is essential. (The Lancet, 2024)
Physical Examination: Assess uterine tone (boggy uterus suggests atony), inspect for lacerations (cervix, vagina, perineum), check for retained placental fragments (visual inspection of placenta, uterine exploration). (The Lancet, 2024)
Laboratory Tests: Initial CBC (Hb, Hct), coagulation profile (PT, aPTT, fibrinogen), type and cross-match for blood products. (The Lancet, 2024)

Early identification of risk factors (e.g., grand multiparity, multiple gestation, prolonged labour, history of PPH) allows for proactive management and preparedness. (The Lancet, 2024)

💊 TREATMENT PROTOCOL

Immediate Steps (Simultaneous Actions)

Call for Help: Activate PPH protocol/emergency team. (The Lancet, 2024)
ABC Assessment: Airway, Breathing, Circulation – ensure patent airway, administer oxygen. (The Lancet, 2024)
Resuscitation: Establish two large-bore IV lines (14-16 gauge), rapid infusion of crystalloids (e.g., warmed Ringer’s lactate) and blood products (e.g., O-negative if uncrossmatched, then type-specific). (The Lancet, 2024)
Identify Cause & Manage: Implement the “4 T’s” approach. (The Lancet, 2024)

Pharmacological Management (Uterotonics)

Oxytocin: First-line for uterine atony. 10 IU IV bolus (slow push) followed by infusion of 20-40 IU in 1L crystalloid at 125-250 mL/hr. (The Lancet, 2024)
Tranexamic Acid: Administer 1g IV over 10 minutes, ideally within 3 hours of bleeding onset, repeated once after 30 minutes if bleeding continues. Reduces mortality from PPH. (The Lancet, 2024)
Methylergonovine (Methergine): 0.2 mg IM, repeat every 2-4 hours up to 5 doses. Contraindicated in hypertension, pre-eclampsia. (The Lancet, 2024)
Carboprost (Hemabate): 250 mcg IM or intramyometrial, repeat every 15-90 minutes up to 8 doses. Contraindicated in asthma. (The Lancet, 2024)
Misoprostol: 800-1000 mcg rectally. Can be used as an alternative or adjunct. (The Lancet, 2024)

Mechanical & Surgical Management

Uterine Massage: Continuous, firm fundal massage to stimulate uterine contraction. (The Lancet, 2024)
Bimanual Uterine Compression: Manual compression of the uterus to arrest bleeding, while other interventions are prepared. (The Lancet, 2024)
Balloon Tamponade: Bakri balloon or other devices can be inserted into the uterus and inflated to apply direct pressure to the uterine walls, effective for atonic bleeding. (The Lancet, 2024)
Uterine Artery Embolization: Radiologically guided procedure to occlude uterine arteries. (The Lancet, 2024)
Surgical Interventions:
- Laceration Repair: Identify and repair any cervical, vaginal, or perineal lacerations. (The Lancet, 2024)
- Exploration of Uterus & Removal of Retained Tissue: Manual removal of placenta or clots. (The Lancet, 2024)
- Compressive Sutures: B-Lynch, Hayman, or Cho sutures to compress the uterus. (The Lancet, 2024)
- Ligation of Uterine/Internal Iliac Arteries: Surgical ligation to reduce blood flow. (The Lancet, 2024)
- Hysterectomy: Last resort for refractory PPH, life-saving procedure. (The Lancet, 2024)

Massive Transfusion Protocol

Activate for severe PPH or signs of shock. Involves rapid administration of packed red blood cells, fresh frozen plasma, and platelets in specific ratios (e.g., 1:1:1 or 6:4:1). Monitor coagulation status closely. (The Lancet, 2024)

⚠️ SAFETY & MONITORING

Continuous Vital Sign Monitoring: Heart rate, blood pressure, respiratory rate, oxygen saturation. Deviations indicate worsening status. (The Lancet, 2024)
Quantitative Blood Loss Assessment: Regular, objective measurement of blood loss to guide therapy and avoid underestimation. (The Lancet, 2024)
Urine Output: Catheterize for accurate measurement (e.g., hourly), indicating renal perfusion. (The Lancet, 2024)
Coagulation Status: Repeat CBC, PT, aPTT, fibrinogen, D-dimer to monitor for coagulopathy and guide blood product transfusion. (The Lancet, 2024)
Fluid Balance: Meticulous charting of IV fluid intake and urine output. (The Lancet, 2024)
Temperature: Maintain normothermia to prevent coagulopathy. (The Lancet, 2024)
Mental Status: Assess for signs of cerebral hypoperfusion (e.g., confusion, lethargy). (The Lancet, 2024)
Communication: Clear and concise communication among the multidisciplinary team members is paramount. (The Lancet, 2024)

🔥 CLINICAL IMPLICATIONS

Reduced Maternal Mortality and Morbidity: Prompt and structured management significantly reduces adverse outcomes for mothers. (The Lancet, 2024)
Standardization of Care: Implementation of PPH bundles and protocols ensures a consistent and effective response, regardless of provider or setting. (The Lancet, 2024)
Enhanced Team Training: Regular drills and simulations improve team coordination, decision-making, and rapid execution of interventions. (The Lancet, 2024)
Resource Allocation: Highlights the need for adequate availability of uterotonics, blood products, and surgical capabilities. (The Lancet, 2024)
Patient Safety Culture: Fosters an environment where PPH is treated as a critical emergency requiring immediate and aggressive intervention, improving overall patient safety in obstetrics. (The Lancet, 2024)
Long-term Impact: Avoiding PPH complications can prevent long-term health issues such as Sheehan’s syndrome, chronic anemia, and psychological trauma. (The Lancet, 2024)

💡 5 CLINICAL PEARLS

Measure, Don’t Guess: Quantitative blood loss measurement (QBL) is superior to visual estimation and critical for timely diagnosis and management. (The Lancet, 2024)
The 4 T’s Drive Management: Always consider Tone, Trauma, Tissue, and Thrombin simultaneously to identify and address the root cause of bleeding. (The Lancet, 2024)
Time is Myometrial Tissue: Uterine atony requires immediate pharmacological intervention with uterotonics; delays lead to progressive blood loss and poorer outcomes. (The Lancet, 2024)
Tranexamic Acid Early: Administer 1g IV Tranexamic Acid within 3 hours of PPH onset; it significantly reduces PPH mortality. (The Lancet, 2024)
Multidisciplinary Team is Key: A well-rehearsed, coordinated response from obstetrics, anaesthesia, nursing, and blood bank personnel saves lives. (The Lancet, 2024)

🧬 DIFFERENTIAL DIAGNOSIS

While PPH is often attributed to the “4 T’s,” it’s crucial to consider other conditions that may mimic or exacerbate bleeding in the postpartum period:

Ruptured Uterus: Although more common antenatally or intrapartum, it can present postpartum, especially with prior uterine surgery. (The Lancet, 2024)
Uterine Inversion: A rare but severe complication where the uterine fundus collapses into the endometrial cavity or protrudes through the cervix. (The Lancet, 2024)
Placenta Accreta Spectrum (PAS): Abnormal adherence of the placenta to the uterine wall, leading to severe haemorrhage at attempted manual removal. (The Lancet, 2024)
Vaginal/Vulvar Hematoma: Can accumulate significant amounts of blood, causing pain and hypovolemia, especially after operative vaginal delivery. (The Lancet, 2024)
Disseminated Intravascular Coagulation (DIC): Can be a cause or a consequence of severe PPH, making bleeding refractory to uterotonics. (The Lancet, 2024)
Pre-existing Coagulopathies: Inherited bleeding disorders (e.g., von Willebrand disease) or acquired (e.g., ITP, anticoagulant use). (The Lancet, 2024)
Sepsis: Can cause coagulopathy and uterine atony, complicating PPH. (The Lancet, 2024)
Retained Products of Conception (RPOC): Even after a manual removal, small fragments can remain and impede uterine contraction. (The Lancet, 2024)

📚 REFERENCES

The Lancet. (2024). Series: Diagnosis and treatment of postpartum haemorrhage: a race against time. General Internal Medicine.

🎓 20 MASTER EXAM VIVA QUESTIONS

📝 Click for 20 Viva Questions

Q1. Define primary postpartum haemorrhage and state its critical diagnostic threshold. What makes visual estimation problematic?

A1. Primary PPH is defined as blood loss of 500 mL or more within 24 hours after vaginal birth, or 1000 mL or more after a caesarean section. The critical diagnostic threshold for severe PPH is 1000 mL, irrespective of delivery mode. Visual estimation is problematic because it consistently underestimates actual blood loss, often by as much as 30-50%, leading to delayed recognition and intervention. (The Lancet, 2024)

Q2. Enumerate the “4 T’s” of PPH causes and briefly explain the most common one.

A2. The “4 T’s” are Tone (uterine atony), Trauma (lacerations, uterine rupture), Tissue (retained placental tissue or clots), and Thrombin (coagulopathy). The most common cause is Tone (uterine atony), accounting for 70-80% of cases, where the uterus fails to contract adequately after delivery, leaving uterine blood vessels open and bleeding. (The Lancet, 2024)

Q3. Outline the immediate resuscitative steps for a patient presenting with severe PPH.

A3. Immediate steps include calling for help and activating the PPH protocol, assessing ABCs (Airway, Breathing, Circulation) and administering high-flow oxygen, establishing two large-bore IV lines (14-16 gauge), and initiating rapid infusion of warmed crystalloids (e.g., Ringer’s lactate) and cross-matched or O-negative blood products. (The Lancet, 2024)

Q4. Discuss the role and timing of Tranexamic Acid in PPH management.

A4. Tranexamic Acid (TXA) is an antifibrinolytic that reduces bleeding by inhibiting the breakdown of fibrin clots. It should be administered as 1g IV over 10 minutes, ideally within 3 hours of PPH onset, and can be repeated once after 30 minutes if bleeding continues. Early administration has been shown to reduce mortality from PPH. (The Lancet, 2024)

Q5. What are the first-line uterotonic agents for uterine atony, and what is their mechanism of action?

A5. Oxytocin is the first-line uterotonic for uterine atony. Its mechanism of action is to stimulate smooth muscle contraction of the uterus, leading to constriction of blood vessels within the myometrium, thereby reducing bleeding from the placental site. (The Lancet, 2024)

Q6. A patient with PPH has a history of asthma. Which uterotonic should be avoided, and what alternative would you consider?

A6. Carboprost (Hemabate) should be avoided in patients with asthma due to its prostaglandin F2α analogue action, which can cause bronchoconstriction. Misoprostol (a prostaglandin E1 analogue) or Methylergonovine could be considered as alternatives, provided there are no contraindications such as hypertension for the latter. (The Lancet, 2024)

Q7. Explain the principle behind uterine balloon tamponade for PPH. When is it indicated?

A7. Uterine balloon tamponade (e.g., Bakri balloon) works by providing direct pressure against the inner uterine wall, compressing the bleeding vessels and promoting hemostasis. It is indicated for uterine atony that is refractory to uterotonic medications, especially when conservative management is desired to preserve fertility. (The Lancet, 2024)

Q8. What are the key elements of monitoring for a patient actively bleeding from PPH?

A8. Key elements include continuous monitoring of vital signs (HR, BP, RR, SpO2), quantitative assessment of blood loss, hourly urine output via Foley catheter, frequent assessment of uterine tone, and serial laboratory tests (CBC, coagulation profile: PT/aPTT, fibrinogen). (The Lancet, 2024)

Q9. When would you consider activating a massive transfusion protocol in PPH?

A9. A massive transfusion protocol should be activated for severe PPH where blood loss is ongoing and rapidly exceeding 1500-2000 mL, or when there are signs of hypovolemic shock refractory to initial fluid resuscitation, or if the patient has received 4 units of PRBCs and is still actively bleeding. (The Lancet, 2024)

Q10. Name two surgical interventions for refractory PPH that aim to preserve the uterus.

A10. Two surgical interventions aiming to preserve the uterus for refractory PPH include uterine compressive sutures (e.g., B-Lynch, Hayman, Cho sutures) and ligation of the uterine or internal iliac arteries. (The Lancet, 2024)

Q11. What is secondary PPH, and what are its common causes?

A11. Secondary PPH refers to abnormal or excessive bleeding that occurs from 24 hours postpartum up to 12 weeks postpartum. Common causes include retained products of conception (most frequent), endometritis (infection), subinvolution of the placental site, or very rarely, inherited coagulopathies. (The Lancet, 2024)

Q12. Discuss the importance of a multidisciplinary team in managing severe PPH.

A12. A multidisciplinary team (obstetrician, anaesthesiologist, nurses, midwives, blood bank, sometimes interventional radiologist/general surgeon) ensures a coordinated, rapid, and comprehensive response. Each member brings specific expertise (e.g., airway management, blood product allocation, surgical skill, medication administration), optimizing patient care and outcomes in a critical, time-sensitive situation. (The Lancet, 2024)

Q13. List at least three risk factors for PPH.

A13. Risk factors for PPH include grand multiparity, multiple gestation, prolonged labour, history of previous PPH, chorioamnionitis, polyhydramnios, uterine fibroids, and magnesium sulfate administration. (The Lancet, 2024)

Q14. How does uterine inversion present, and what is the initial management?

A14. Uterine inversion presents with sudden, severe abdominal pain, vaginal bleeding, hypovolemic shock out of proportion to estimated blood loss, and often a palpable mass in the vagina or protruding from the introitus. Initial management involves immediate manual replacement of the uterus by the care provider, often requiring uterine relaxants (e.g., nitroglycerin, terbutaline) and aggressive fluid resuscitation. (The Lancet, 2024)

Q15. What are the contraindications for Methylergonovine?

A15. Methylergonovine is contraindicated in patients with hypertension, pre-eclampsia, eclampsia, or significant cardiac disease due to its vasoconstrictive properties which can lead to dangerously elevated blood pressure. (The Lancet, 2024)

Q16. Explain how quantitative blood loss (QBL) measurement can be implemented in practice.

A16. QBL implementation involves using calibrated collection bags under the patient’s buttocks, weighing blood-soaked pads and drapes (1g = 1mL), and calculating blood lost in irrigation fluids. This provides a more objective and accurate assessment of blood loss compared to visual estimation. (The Lancet, 2024)

Q17. When is hysterectomy indicated for PPH, and what are its long-term implications?

A17. Hysterectomy is indicated as a life-saving measure for refractory PPH when all other medical and surgical interventions have failed, and bleeding is uncontrollable. Long-term implications include permanent infertility, potential for hormonal imbalances if ovaries are removed, and significant psychological impact on the patient. (The Lancet, 2024)

Q18. What is the significance of maintaining normothermia during severe PPH?

A18. Maintaining normothermia is critical because hypothermia can exacerbate coagulopathy, impair platelet function, and reduce the effectiveness of clotting factors, thereby worsening bleeding and increasing the risk of adverse outcomes in PPH. (The Lancet, 2024)

Q19. How can retained placental tissue be identified and managed in PPH?

A19. Retained placental tissue can be identified by inspecting the placenta for missing cotyledons, palpating a boggy uterus with persistent bleeding despite uterotonics, or through ultrasound. Management involves manual exploration of the uterine cavity to remove any remaining fragments, often performed under adequate analgesia or anaesthesia. (The Lancet, 2024)

Q20. Beyond immediate survival, what are some potential long-term complications or sequelae of severe PPH?

A20. Long-term complications of severe PPH can include Sheehan’s syndrome (panhypopituitarism due to pituitary necrosis), chronic anemia, infertility (especially after hysterectomy), psychological trauma (PTSD, depression), secondary amenorrhea, and Asherman’s syndrome (intrauterine adhesions) from uterine instrumentation. (The Lancet, 2024)

Generated by: Gemini AI

Keywords: General Internal Medicine, clinical update, evidence-based medicine, The Lancet, medical education, internal medicine exam preparation, 2026 clinical guidelines

Related Resources:

Disclaimer: This content is auto-generated for educational purposes. Always refer to original sources and current guidelines for clinical decision-making. Last updated: June 13, 2026

[General Internal Medicine] [Series] Diagnosis and treatment of postpartum haemorrhage: a race against time